August 13, 2019

Neil Kumar, Ph.D.
Chief Executive Officer
Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2550
San Francisco, CA 94104

       Re: Eidos Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed August 2, 2019
           File No. 333-232999

Dear Dr. Kumar:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this comment, we may have additional comments.

Registration Statement on Form S-3 filed August 2, 2019

Description of Capital Stock, page 7

1.     We note that Article VI, Section 8 of your Amended and Restated Bylaws
includes a
       forum selection provision listing the Court of Chancery of the State of
Delaware as the
       sole and exclusive forum for certain litigation, including any
"derivative action." Please
       describe this provision here and include a risk factor addressing the
risks to investors
       posed by the exclusive forum provision. In your disclosure, please also
discuss whether
       the provision applies to actions arising under the Securities Act or
Exchange Act. In that
       regard, we note that Section 27 of the Exchange Act creates exclusive
federal jurisdiction
       over all suits brought to enforce any duty or liability created by the
Exchange Act or the
       rules and regulations thereunder, and Section 22 of the Securities Act
creates concurrent
       jurisdiction for federal and state courts over all suits brought to
enforce any duty or
       liability created by the Securities Act or the rules and regulations
thereunder. If the
 Neil Kumar, Ph.D.
Eidos Therapeutics, Inc.
August 13, 2019
Page 2
      provision applies to Securities Act claims, please also disclose that
there is uncertainty as
      to whether a court would enforce such provision and that investors cannot
waive
      compliance with the federal securities laws and the rules and regulations
thereunder. If
      this provision does not apply to actions arising under the Securities Act
or Exchange Act,
      please also ensure that the exclusive forum provision in the governing
documents states
      this clearly, or tell us how you will inform investors in future filings
that the provision
      does not apply to any actions arising under the Securities Act or
Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Irene Paik at 202-551-6553 or Mary Beth Breslin at
202-551-3625 with
any questions.



                                                             Sincerely,
FirstName LastNameNeil Kumar, Ph.D.
                                                             Division of
Corporation Finance
Comapany NameEidos Therapeutics, Inc.
                                                             Office of
Healthcare & Insurance
August 13, 2019 Page 2
cc:       Maggie Wong - Goodwin Procter LLP
FirstName LastName